Altimmune(US:ALT) Globenewswire·2025-10-20 11:30Core Insights - Altimmune, Inc. is set to present 24-week efficacy and safety data from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) at The Liver Meeting 2025 [1][4] - The company anticipates announcing 48-week data in Q4 2025, indicating ongoing development and potential for further insights into the treatment's effectiveness [4] Presentation Details - The late-breaking presentations will focus on the recent 24-week data readout from the IMPACT Phase 2b trial [4] - A poster will feature AI-based analyses of liver fibrosis reduction, showcasing innovative approaches in the study [1][8] Study Overview - The IMPACT trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive weekly subcutaneous pemvidutide doses of either 1.2 mg, 1.8 mg, or placebo for 24 weeks [5] - Key efficacy endpoints include MASH resolution without worsening of fibrosis and fibrosis improvement without worsening of MASH at 24 weeks, with secondary endpoints focusing on weight loss and non-invasive tests of fibrosis [5] About Pemvidutide - Pemvidutide is a novel peptide-based dual receptor agonist targeting GLP-1 and glucagon receptors, aimed at treating MASH, Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) [6] - The FDA has granted Fast Track designations for pemvidutide in both MASH and AUD, highlighting significant unmet medical needs in these areas [6] Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead product candidate [9]